Ignite Creation Date:
2024-10-25 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06523465
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-17
Brief Title:
Statin Combined With Amlodipine Treats Primary Aldosteronism
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Multi-center Randomized Trial to Compare Statin Combined With CCB to MRA Combined With CCB in Primary Aldosteronism Treatment
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STOP-PA
Brief Summary:
The drug treatment for primary aldosteronism PA is limited and difficult to improve long-term cardiovascular outcomes This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups scheme 1 Statin combined with amlodipine besylate scheme 2 Statin combined with Spironolactone and Amlodipine besylate scheme 3 Amlodipine besylate combined with Spironolactone to observe the changes in plasma aldosterone level 24-hour urinary aldosterone blood pressure and long-term cardiovascular risk
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None